Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Purchases $13,064.70 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 3,959 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average price of $3.30 per share, for a total transaction of $13,064.70. Following the acquisition, the insider directly owned 82,556 shares of the company’s stock, valued at $272,434.80. The trade was a 5.04% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of Shuttle Pharmaceuticals stock traded up $0.03 during midday trading on Thursday, reaching $3.43. 160,775 shares of the company’s stock traded hands, compared to its average volume of 550,761. Shuttle Pharmaceuticals Holdings, Inc. has a 52 week low of $2.90 and a 52 week high of $55.90. The company’s 50 day simple moving average is $5.93 and its 200 day simple moving average is $10.74. The company has a market cap of $2.20 million, a price-to-earnings ratio of -0.07 and a beta of 0.29.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SHPH. Connective Capital Management LLC bought a new position in Shuttle Pharmaceuticals during the third quarter valued at about $357,000. Ikarian Capital LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $124,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Finally, Geode Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth about $26,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .